1-20 of 27
Meghan C. Thompson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Nicole Lamanna, Jennifer R. Brown, Chaitra S. Ujjani, Toby A. Eyre, Beenish Manzoor, Nilanjan Ghosh, Lindsey Roeker, Matthew S. Davids, Catherine C Coombs, Alan P Skarbnik, Brian T. Hill, Hande H. Tuncer, Lori A. Leslie, Joanna M. Rhodes, Isabelle Fleury, Paul M Barr, Nnadozie Emechebe, Nicolas Martinez-Calle, Christopher E. Jensen, Yun Choi, Dureshahwar Jawaid, Laurie K Pearson, Meghan C. Thompson, Steven E Marx, Wendy J. Sinai, Frederick Lansigan, Bita Fakhri, Deborah M. Stephens, Stephen J. Schuster, Michael Coyle, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2024) 144 (Supplement 1): 4625.
https://doi.org/10.1182/blood-2024-205223
Published: 2024
Journal Articles

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Meghan C. Thompson, Seema A. Bhat, Wojciech Jurczak, Krish Patel, Nirav N. Shah, Jennifer A. Woyach, Catherine C. Coombs, Toby A. Eyre, Michal Danecki, Monika Dlugosz-Danecka, Neil Bailey, Joanna M. Rhodes, Nicole Lamanna, Andrew H. Lipsky, Jeffrey Jensen, Adam Kidwell, Eytan M. Stein, Monica Shah, Jennifer R. Brown, Andriy Derkach, Anthony R. Mato, Lindsey Roeker
Journal: Blood
Blood (2024) 144 (Supplement 1): 1870.
https://doi.org/10.1182/blood-2024-194748
Published: 2024
Journal Articles

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Jacob D. Soumerai, Ahmet Dogan, Venkatraman Seshan, Kelsey Leigh Flaherty, Natalie Slupe, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Audrey Hamilton, Ariela Noy, Colette Owens, Maria Lia Palomba, Anita Kumar, Lindsey Roeker, Meghan C. Thompson, Ronald W. Takvorian, Zachary D. Epstein-Peterson, Mark Blaine Geyer, Gilles Salles, Robert Stuver, Philip Caron, Prioty Islam, Tamanna Haque, Paola Ghione, Raphael E. Steiner, Pallawi Torka, Kevin A. David, Jennifer Kimberly Lue, Paul A. Hamlin, Alison Moskowitz, Lorenzo Falchi, Julie Haydu, Patrick Connor Johnson, Joanna Mi, Jessica Pendleton, Alyssa Labarre, Rosalba Martignetti, Sean F. Plummer, Maria Chabowska, Walter Ramos Amador, Neena Mahajan, Morgan Choma, Clare Grieve, Rayna N. Garcia, Hailey E. Kelly, Ella Mallinger, James O'Grady, Bernadette Beatty, Michelle Adams, Athina Apazidis, Aileen Cleary Cohen, Mina Shahkarami, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood
Blood (2024) 144 (Supplement 1): 1867.
https://doi.org/10.1182/blood-2024-205697
Published: 2024
Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Meghan C. Thompson, Ricardo D. Parrondo, Anna Maria Frustaci, John N. Allan, Paolo Ghia, Irina Mocanu, Constantine S. Tam, Judith Trotman, Inhye E. Ahn, Stephan Stilgenbauer, Lydia Scarfo, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, John F. Seymour
Journal: Blood
Blood (2024) 144 (Supplement 1): 885.
https://doi.org/10.1182/blood-2024-199116
Published: 2024
Journal Articles

Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Lindsey Roeker, Anthony R. Mato, Andrew D. Zelenetz, Jae H. Park, Mark Blaine Geyer, Andriy Derkach, David Nemirovsky, Prioty Islam, Lorenzo Falchi, Maria Lia Palomba, Anita Kumar, Gilles Salles, Jennifer Kimberly Lue, Aaron D. Goldberg, Deborah M. Stephens, Victoria Duffy, Gail Panton, Dianna Tyznar, Colleen Dorsey, Dhara Soni, Claire Hutzler, Lauren Nogan, Alexandra Allen, Tenzin Nyima, Thu Quynh Nguyen, Monica Shah, Tamotha R Cook, Jennifer Abillar-Wright, Jamila Brutus, Carissa Laudati, Bejal Kikani, Catherine C Coombs, Michael R. Silvestrone, Christopher E. Jensen, Bita Fakhri, Meghan C. Thompson
Journal: Blood
Blood (2024) 144 (Supplement 1): 1010.
https://doi.org/10.1182/blood-2024-203807
Published: 2024
Journal Articles

Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1

Alexey Danilov, Bita Fakhri, Farrukh T. Awan, Hans Herluf Bentzen, Herbert A. Eradat, Carsten Utoft Niemann, Fritz Offner, Christian Bjørn Poulsen, Thor Hoeyer, Mar Bellido, Damien Roos Weil, Alessandra Ferrajoli, Meghan C. Thompson, Jacob Haaber Christensen, Ann Janssens, Tamar Tadmor, Mazyar Shadman, Pegah Jafarinasabian, Jimin Zhang, Marcia Rios, Alexandra Kuznetsova, Rebecca Valentin, Arnon P. Kater
Journal: Blood
Blood (2024) 144 (Supplement 1): 883.
https://doi.org/10.1182/blood-2024-199708
Published: 2024
Journal Articles

A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL

Cecelia Miller, Ying Huang, John N. Allan, Seema A. Bhat, David A. Bond, Danielle M. Brander, John C. Byrd, Julio C. Chavez, Elise A. Chong, Alexey Danilov, Mark R Dowling, Kaitlyn M. Dvorak-Kornaus, Paul J. Hampel, Carrie I Ho, Prioty Islam, Nikita Malakhov, Matthew Matasar, Sarah Miller, Sameer A. Parikh, Kari G. Rabe, Joanna M. Rhodes, Lindsey Roeker, Kerry A. Rogers, Aditi Saha, Alan P Skarbnik, Hamish W Scott, Jake Schade, Mazyar Shadman, Geoffrey Shouse, Deborah M. Stephens, Meghan C. Thompson, Philip A. Thompson, Yucai Wang, Jennifer A. Woyach, Max Yano, Zulfa Omer, Adam S Kittai
Journal: Blood
Blood (2024) 144 (Supplement 1): 3245.
https://doi.org/10.1182/blood-2024-205668
Published: 2024
Journal Articles

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

John F. Seymour, Chan Yoon Cheah, Ricardo Parrondo, Meghan C. Thompson, Don A. Stevens, Masa Lasica, Michael L. Wang, Abhijeet Kumar, Judith Trotman, Maan Alwan, Wei Ding, Kunthel By, Bilal Tariq, Xiangmei Chen, Shannon Fabre, Jason Paik, Amit Agarwal, Constantine S. Tam
Journal: Blood
Blood (2023) 142 (Supplement 1): 4401.
https://doi.org/10.1182/blood-2023-180109
Published: 2023
Journal Articles

A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Andrew L. Sochacki, Jan A. Burger, Carrianne Ludwig, Wissam Assaily, Wijith Munasinghe, William Pappano, Edward Greenberg, Christine Will, Meghan C. Thompson
Journal: Blood
Blood (2023) 142 (Supplement 1): 3101.
https://doi.org/10.1182/blood-2023-181671
Published: 2023
Journal Articles

Ruxolitinib Promotes Clinical Responses in Large Granular Lymphocytic Leukemia Via Suppression of JAK/STAT-Dependent Inflammatory Cascades

Alison Moskowitz, Jahan Rahman, Nivetha Ganesan, Kelly Hannigan, Katie Ksanznak, Hadassah Bitton, Ya-Hui Lin, Theresa Davey, Helen Hancock, Leslie Perez, Tayler Miller, Jamila Brutus, Ahmet Dogan, Mark Blaine Geyer, Eric Jacobsen, Anita Kumar, Jonathan Moreira, Jae H. Park, Meghan C. Thompson, Pallawi Torka, Andrew D. Zelenetz, Santosha A Vardhana, Steven M. Horwitz
Journal: Blood
Blood (2023) 142 (Supplement 1): 183.
https://doi.org/10.1182/blood-2023-181922
Published: 2023
Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Alexey Danilov, Michael T. Tees, Krish Patel, William G. Wierda, Manish Patel, Ian W. Flinn, Tahir Latif, Weiyun Ai, Meghan C. Thompson, Michael L. Wang, Clare Sun, Deborah M. Stephens, Michael J Thirman, Melissa Gessner, Johannes Wolff, Amanda Schwab, May Tan, Daniel Chan, Erin Meredith, Adrian Wiestner
Journal: Blood
Blood (2023) 142 (Supplement 1): 4463.
https://doi.org/10.1182/blood-2023-179872
Published: 2023
Journal Articles

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Adam S Kittai, Ying Huang, Sarah Miller, John N. Allan, Seema A Bhat, David A. Bond, Danielle M Brander, John C. Byrd, Julio C Chavez, Elise A. Chong, Matthew S Davids, Alexey Danilov, Wei Ding, Mark R Dowling, Kaitlyn M. Dvorak-Kornaus, Hannah Freedman, Paul J Hampel, Carrie I Ho, Steven R Hwang, Prioty Islam, Nitin Jain, Matthew Matasar, Cecelia Miller, Erin M Parry, Kari G. Rabe, Manoj Rai, Phil Raess, Lindsey E. Roeker, Joanna M. Rhodes, Kerry A Rogers, Aditi Saha, Jake Schade, Hamish S Scott, Mazyar Shadman, Geoffrey P. Shouse, Alan Skarbnik, Stephen E Spurgeon, Deborah M. Stephens, Meghan C. Thompson, Philip A. Thompson, Yucai Wang, William G. Wierda, Max Yano, Omer Zulfa, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (Supplement 1): 497.
https://doi.org/10.1182/blood-2023-182114
Published: 2023
Journal Articles

A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation

Lindsey E. Roeker, Andrew D. Zelenetz, Jae H. Park, Andriy Derkach, Mark Blaine Geyer, Prioty Islam, Lorenzo Falchi, Maria Lia Palomba, Anita Kumar, Gilles Salles, Jennifer Kimberly Lue, Aaron D. Goldberg, Bita Fakhri, Catherine C. Coombs, Victoria Falco, Gail Panton, Dianna Tyznar, Dhara Soni, Lauren Nogan, Sonia Lebowitz, Katherine Blesie, Monica Shah, Sarah Court, Christopher E. Jensen, Anthony R. Mato, Meghan C. Thompson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4657.
https://doi.org/10.1182/blood-2023-181661
Published: 2023
Journal Articles

Chemotherapy-Sparing Induction Followed By Consolidation and Maintenance with Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Primary Endpoint Results from the Blissphall Study

Mark Blaine Geyer, John Mascarenhas, Marissa Smith, Shakira Pascual, Anmol Shah, Michael R. Silvestrone, Tina Czaplinska, Kathryn Johnson, Meghan C. Thompson, Jae H. Park
Journal: Blood
Blood (2023) 142 (Supplement 1): 1510.
https://doi.org/10.1182/blood-2023-173551
Published: 2023
Journal Articles

Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders

Skye Montoya, Jessie Bourcier, Meghan C. Thompson, Mark Noviski, May Tan, Eric Wang, Xiaoli Mi, Nivetha Brathaban, Carla Barrientos Risso, Daniel Tsai, Jordan Ye, Jacob Jahn, Gabriel Pardo, Lee Cabuhat, Ryan Notti, Alejandro Pardo, Maurizio Affer, Stephanie Yung, James Luliano, Janine Powers, Daniel W Robbins, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M. Rhodes, Andrew D. Zelenetz, Lindsey E. Roeker, Hao Lu, Adam Linley, Anthony R. Mato, Omar Abdel-Wahab, Justin Taylor
Journal: Blood
Blood (2022) 140 (Supplement 1): 1811–1813.
https://doi.org/10.1182/blood-2022-163268
Published: 2022
Journal Articles

Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation

Meghan C. Thompson, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey L. Jensen, Nirav N. Shah, Thomas Luo, Krish Patel, Neil Bailey, Bita Fakhri, Toby A. Eyre, Paola Ghione, Joanna M. Rhodes, Andrew D. Zelenetz, Justin Taylor, Maria Lia Palomba, Kendall Meyer, Danielle Rao, Yehudit Fox, Julia H. Aronson, Sarah Court, Omar Abdel-Wahab, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 9885–9888.
https://doi.org/10.1182/blood-2022-159133
Published: 2022
Journal Articles

Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Nirav N. Shah, Michael L. Wang, Jennifer R. Brown, Krish Patel, Jennifer A. Woyach, William G. Wierda, Chaitra S. Ujjani, Toby A. Eyre, Pier Luigi Zinzani, Alvaro J. Alencar, Thomas Gastinne, Paolo Ghia, Nicole Lamanna, Marc Hoffmann, Manish R. Patel, Ian W. Flinn, James N. Gerson, Shuo Ma, Catherine C. Coombs, Chan Y. Cheah, Ewa Lech-Marańda, Bita Fakhri, Won-Seog Kim, Minal A. Barve, Jonathon B. Cohen, Wojciech Jurczak, Talha Munir, Meghan C. Thompson, Lindsey E. Roeker, Katherine Bao, Nicholas A. Cangemi, Jennifer F. Kherani, Richard A. Walgren, Hongmei Han, Amy S. Ruppert, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 4127–4132.
https://doi.org/10.1182/blood-2022-159035
Published: 2022
Journal Articles

Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

Meghan C. Thompson, Lindsey E. Roeker, Catherine C. Coombs, Jeffrey L. Jensen, Manali Kamdar, Alan Skarbnik, John M. Pagel, Neil Bailey, Jeffrey J. Pu, Ryan Jacobs, Brian T. Hill, Danielle M. Brander, Mazyar Shadman, Chaitra S. Ujjani, Kristen E. Battiato, Celina J. Komari, Guilherme Sacchi De Camargo Correia, Julia H. Aronson, Joanna M Rhodes, Paola Ghione, Bita Fakhri, Paul M. Barr, Craig A. Portell, Nicole Lamanna, Javier Pinilla-Ibarz, Andrew D. Zelenetz, Stephen J Schuster, John N. Allan, Toby A. Eyre, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 2628.
https://doi.org/10.1182/blood-2021-150751
Published: 2021
Journal Articles

Outcomes of Chronic Lymphocytic Leukemia and Richter Transformation Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors

Meghan C. Thompson, Catherine C. Coombs, Lindsey E. Roeker, John M. Pagel, Jeffrey L. Jensen, Kristen E. Battiato, Yehudit Fox, Kendall Meyer, Neil Bailey, Joanna M Rhodes, Paola Ghione, Bita Fakhri, Toby A. Eyre, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 2629.
https://doi.org/10.1182/blood-2021-148592
Published: 2021
Journal Articles

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Jacob D. Soumerai, Anthony R. Mato, Ahmet Dogan, Venkatraman Seshan, Erel Joffe, Kelsey Flaherty, Jason Carter, Ephraim P Hochberg, Jeffrey A Barnes, Audrey Hamilton, Jeremy S. Abramson, Connie Lee Batlevi, Matthew J. Matasar, Ariela Noy, Colette Owens, M. Lia Palomba, Anita Kumar, Tak Takvorian, Ai Ni, Morgan Choma, Chaya Friedman, Puja Chadha, Elizabeth Simkins, Jade Ruiters, Sidney Sechio, Daneal Portman, Natascha Nolet, Neena Mahajan, Rosalba Martignetti, Joanna Mi, Krista J Scorsune, Julia M Lynch, Brianne McGree, Stephanie Y Hughes, Clare Grieve, Lindsey E. Roeker, Meghan C. Thompson, P. Connor Johnson, Mikhail Roshal, Jane Huang, Juliana M.L. Biondo, Jenny Qun Wu, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz
Journal: Blood
Blood (2021) 138 (Supplement 1): 3753.
https://doi.org/10.1182/blood-2021-150961
Published: 2021